drugset / Trial / NCT05242029

Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use

NCT05242029 ↗

Phase 2 Withdrawn Johns Hopkins University
RandomizedCrossoverQuadruple-blindTreatment

Summary

This study will investigate whether psilocybin administered under supportive conditions can reduce illicit opioid use and improve quality of life in individuals with Opioid Use Disorder (OUD) in Methadone Maintenance Treatment (MMT) who are concurrently using other opioids illicitly.

Timeline

Start
2023-12
Primary completion
2024-02
Completion
2024-12

Outcome

Outcome not reported

Stopped (Business): “Lack of funding”

Drugs

EvaluationDrugModalityDoseRoute
Subject Psilocybin Other / unclassified 40 mg Oral